TY - JOUR
T1 - Early haemostatic therapy for spontaneous intracranial haemorrhage
AU - Micieli, Giuseppe
AU - Tosi, P.
AU - Marcheselli, S.
AU - Cavallini, A.
PY - 2005/5
Y1 - 2005/5
N2 - Intracranial haemorrhage (ICH) accounts for approximately 10%-15% of all strokes and is associated with the highest mortality rate and with the highest degree of disability among the survivors compared to all other strokes. The role of surgical and medical treatment is controversial. Recently, a parallel-group trial design between early surgery versus initial conservative treatment in patients with ICH showed no overall benefit from surgery. Several agents could theoretically be used. Activated recombinant factor VII administered within 4 hours after the onset of ICH seems to be the best candidate: in a recent study, it limited the growth of the haematoma, reduced mortality and improved functional outcome at 90 days. Further studies are necessary to define optimal dose of this drug, verify its efficacy and identify patients at high risk for thromboembolic complications.
AB - Intracranial haemorrhage (ICH) accounts for approximately 10%-15% of all strokes and is associated with the highest mortality rate and with the highest degree of disability among the survivors compared to all other strokes. The role of surgical and medical treatment is controversial. Recently, a parallel-group trial design between early surgery versus initial conservative treatment in patients with ICH showed no overall benefit from surgery. Several agents could theoretically be used. Activated recombinant factor VII administered within 4 hours after the onset of ICH seems to be the best candidate: in a recent study, it limited the growth of the haematoma, reduced mortality and improved functional outcome at 90 days. Further studies are necessary to define optimal dose of this drug, verify its efficacy and identify patients at high risk for thromboembolic complications.
KW - Conservative treatment
KW - Early surgery
KW - Intracranial haemorrhage
KW - Recombinant factor VIIa
UR - http://www.scopus.com/inward/record.url?scp=18344376201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18344376201&partnerID=8YFLogxK
U2 - 10.1007/s10072-005-0402-0
DO - 10.1007/s10072-005-0402-0
M3 - Article
C2 - 15883690
AN - SCOPUS:18344376201
VL - 26
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - SUPPL. 1
ER -